The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

TheProductLawyers.com reports on an Ohio couple who have filed a lawsuit against the makers of Xarelto, a blood-thinning drug designed to treat patients afflicted with atrial fibrillation, pulmonary embolism, and deep vein thrombosis (DVT), as well as for those who have undergone hip and knee replacement surgery. The couple’s suit alleges the manufacturers, Janssen Pharmaceuticals, a division of the Johnson and Johnson Corporation, and Bayer AG, failed to properly inform the public and medical professionals about the risks involved with taking Xarelto.

Ohio Couple File Suit

In the Ohio couple’s court documents, they state that the wife was given Xarelto as a treatment for her atrial fibrillation and, as a result, had suffered a gastrointestinal bleed and anemia only two months after beginning her treatment. Because of this internal bleeding, the couple is seeking over $150,000 in compensatory damages to cover both current and future medical bills since she is now additionally being treated for other long-term medical conditions related to the bleeding.

FDA Warnings

Xarelto was approved for release on the market by the U.S. Food and Drug Administration (FDA) in 2011. However, since the agency’s initial approval,  it has issued Xarelto two black box warnings. A black box warning is a very harsh, and usually portends a possible removal of a product from the consumer market.

Consolidation Of Lawsuits

In addition to the Ohio couple, there have been numerous other lawsuits filed in excess of 3,400 and from all across America. In most, if not all of the cases, the plaintiffs uniformly allege that the anticoagulant places patients at a much higher risk for instances of dangerous, and sometimes fatal bleeding. Of the lawsuits filed over 2,800 of the cases have been consolidated into a multidistrict litigation numbered 2592, while another group of over 550 lawsuits has been consolidated into a mass tort program by the Court of Common Pleas in Philadelphia, PA.

Comments for this article are closed.